Logo

Mylan's Remdesivir Lyophilized Powder for Injection Receives the DCGI Accelerated Approval for Restricted Emergency Use in COVID-19 Patients in India

Share this

Mylan's Remdesivir Lyophilized Powder for Injection Receives the DCGI Accelerated Approval for Restricted Emergency Use in COVID-19 Patients in India

Shots:

  • Mylan’s Remdesivir 100mg/vial Lyophilized Powder for Injection will be launched in India under brand name Desrem in Jul with INR 4-800 which is 80% less to the price of its branded version
  • The company will manufacture the product in its injectables facilities in India- which is also inspected by the US FDA for compliance with good manufacturing practices and will be marketed in 127 markets in India
  • Remdesivir is an investigational drug targeted for COVID-19 and has demonstrated favorable outcomes in two P-III trials. Additionally- the US FDA granted EUA to treat hospitalized patients with severe COVID-19 based on the two P-III trials results in the US also recommended for compassionate use in EU including Japan- Taiwan- and Singapore

Click here to read full press release/ article | Ref: PRNewswire | Image: PharmaWorld


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions